Analyst consensus rating
Rapport Therapeutics Analyst Rating: Strong Buy
RAPP is rated Strong Buy by 12 analysts with a $62.05 target. As of 2026-08-22.
Direct answer
Rapport Therapeutics's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $62.05.
Forecast evidence checked August 22, 2026.
Get free Rapport Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $48.24
- Average price target
- $62.05
- High price target
- $80.00
- Low price target
- $50.00
- Low target gap
- +3.6%
- Target upside
- +28.6%
- High target gap
- +65.8%
- Target range width
- 62.2%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Rapport Therapeutics?
Rapport Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $62.05.
How far are Rapport Therapeutics's low and high targets from the recorded price?
The low target implies +3.6%, while the high target implies +65.8%.
How many analysts are included in Rapport Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Rapport Therapeutics's target upside or downside calculated?
The average target of $62.05 is divided by the recorded price of $48.24, then one is subtracted to produce +28.6%. This does not guarantee a future return.
When was Rapport Therapeutics's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.